These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1154 related items for PubMed ID: 28572721

  • 1. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT, Wong YS, Wu CS, Su YH.
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [Abstract] [Full Text] [Related]

  • 2. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M, Naganuma M, Okada Y, Hasegawa Y, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Kario K, Okuda S, Koga M, Minematsu K, Toyoda K.
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [Abstract] [Full Text] [Related]

  • 3. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW, Zhang XJ, Cheng LS, Li GY, Zhang LJ, Ji KX, Zhao Q, Bai Y.
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [Abstract] [Full Text] [Related]

  • 4. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
    Yeo LL, Paliwal P, Teoh HL, Seet RC, Chan BP, Wakerley B, Liang S, Rathakrishnan R, Chong VF, Ting EY, Sharma VK.
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR, Kumaravelu S, Narayan SK, Buddha SS, Murali C, Majeed PHA, Meenakshi-Sundaram S, Wadia RS, Sharma V, Basu I, Vijaya P, Salam KA, Barmare S, Vaid Z, Nirmal Raj KK, Wattamwar PR, Asokan K, Dhonge V, Nellikunja S, Namjoshi D, Srinivasa R, Laddhad DS, Deshpande SD, Raghunath B, Kalita J, Kumar M, Misra UK, Pradeep M, Tenecteplase in Stroke Investigators.
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [Abstract] [Full Text] [Related]

  • 6. The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy.
    Wong YS, Sung SF, Wu CS, Hsu YC, Su YH, Hung LC, Ong CT.
    Drug Des Devel Ther; 2020 Oct; 14():257-263. PubMed ID: 32021109
    [Abstract] [Full Text] [Related]

  • 7. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke.
    Garavaglia J, Sherman J, Yetzer H, Regier M, Smith M.
    J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994
    [Abstract] [Full Text] [Related]

  • 8. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
    Dong Y, Han Y, Shen H, Wang Y, Ma F, Li H, Wang Y, Dong Q.
    Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
    [Abstract] [Full Text] [Related]

  • 9. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW, Kim KJ, Noh WY, Jang MS, Yang MH, Han MK, Kwon OK, Jung C, Kim JH, Oh CW, Lee JS, Lee J, Bae HJ.
    Cerebrovasc Dis; 2013 Dec; 35(5):461-8. PubMed ID: 23735898
    [Abstract] [Full Text] [Related]

  • 10. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M, Tütüncü S, Fiebach JB, Scheitz JF, Audebert HJ, Nolte CH.
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [Abstract] [Full Text] [Related]

  • 11. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
    Alvarez-Sabín J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina A, Quintana M.
    Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
    [Abstract] [Full Text] [Related]

  • 12. Thrombolysis for Acute Minor Stroke: Outcome and Barriers to Management. Results from the RESUVAL Stroke Network.
    Laurencin C, Philippeau F, Blanc-Lasserre K, Vallet AE, Cakmak S, Mechtouff L, Cho TH, Ritzenthaler T, Flocard E, Bischoff M, El Khoury C, Nighoghossian N, Derex L.
    Cerebrovasc Dis; 2015 May; 40(1-2):3-9. PubMed ID: 25998791
    [Abstract] [Full Text] [Related]

  • 13. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
    Hsu YC, Sung SF, Ong CT, Wu CS, Su YH.
    Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
    [Abstract] [Full Text] [Related]

  • 14. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M, Sternberg S, Blackhurst D, Lee A, Leacock R, Nathaniel TI.
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [Abstract] [Full Text] [Related]

  • 15. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Tanahashi N, Yamaguchi T, Awano H, Matsuda H.
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study.
    Zhu X, Wang N, Lin H, Zhang P, Chen L, Zhang M, Deng B, Wu T.
    J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104537. PubMed ID: 31806454
    [Abstract] [Full Text] [Related]

  • 17. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [Abstract] [Full Text] [Related]

  • 18. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.
    Sharma VK, Tsivgoulis G, Tan JH, Wong LY, Ong BK, Chan BP, Teoh HL.
    J Stroke Cerebrovasc Dis; 2010 Apr; 19(6):424-30. PubMed ID: 20554224
    [Abstract] [Full Text] [Related]

  • 19. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE, Monlezun DJ, Siegler JE, Waring ED, Dowell LN, Samai AA, George AJ, Kimbrough T, Berthaud J, Martin-Schild S.
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [Abstract] [Full Text] [Related]

  • 20. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X, Wang Y, Pan Y, Wang C, Zhao X, Wang DZ, Wang C, Liu L, Wang Y, Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China Investigators.
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.